Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new infections, which constitute competing risk events since they can potentially preclude/pre-empt the detection of subsequent recrudescence of persistent, sub-microscopic primary infections.
The potential spread of antimalarial drug resistance to Africa, in particular for artemisinins and key partner drugs, is a major concern.
Tafenoquine is a novel 8-aminoquinoline antimalarial drug recently approved by the U.S. Food and Drug Administration (FDA) for the radical cure of acute Plasmodium vivax malaria, which is the first new treatment in almost 60 years.
The MIC is an essential quantitative measure of the asexual blood-stage effect of an antimalarial drug.
Malaria remains a major infectious disease and, despite incidence reduction, it threatens resurgence in drug-resistant forms.
Government support, as well as innovative incentives and collaboration mechanisms are needed for further adoption of WHO PQ for anti-malarial drugs in China.
Dihydroartemisinin-piperaquine (DHA-PPQ), the current frontline artemisinin combination therapy used to treat Plasmodium falciparum malaria in multiple Southeast Asian countries, is now increasingly failing in Cambodia, where artemisinin resistance is nearly fixed, which suggests that PPQ resistance has emerged and is spreading rapidly in the Greater Mekong Subregion.
Several antimalarial drugs exist, but differences between life cycle stages among malaria species pose challenges for developing more effective therapies.
Resistance to first-line treatments for Plasmodium falciparum malaria and the insecticides used for Anopheles vector control are threatening malaria elimination efforts.
Acquired resistance against antimalarial drugs has further increased the need for an effective malaria vaccine.